OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Recruiting
Observational Study
Cutaneous Leishmaniases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 2 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 80 (estimated)
- Sponsor
- Institute of Tropical Medicine, Belgium · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking. In this study, longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics. This data will be crucial to prov…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Clinical or parasitological (microscopy or PCR) confirmation of leishmaniasis
* Age \>2
* Clinical decision to start miltefosine treatment as systemic treatment
* In case of females of child-bearing age: willing to take contraceptive for 6 months (parenteral or IUD or implant)…
Contacts